Financial Performance - The company's revenue for Q1 2023 reached ¥160,921,094.30, representing a 67.97% increase compared to ¥95,802,322.64 in the same period last year[4] - Net profit attributable to shareholders was ¥35,068,583.71, up 79.56% from ¥19,529,827.85 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥34,554,752.28, reflecting a significant increase of 115.38% compared to ¥16,043,324.96 in the previous year[4] - The basic earnings per share rose to ¥0.32, a 77.78% increase from ¥0.18 in the same period last year[4] - The total operating revenue for Q1 2023 was CNY 160,921,094.30, a significant increase of 68% compared to CNY 95,802,322.64 in Q1 2022[16] - The net profit for Q1 2023 reached CNY 35,109,632.51, up 80% from CNY 19,498,070.83 in the same period last year[17] - The earnings per share (EPS) for Q1 2023 was CNY 0.32, compared to CNY 0.18 in Q1 2022, reflecting a 78% increase[17] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥3,246,045,079.45, a 10.80% increase from ¥2,929,704,604.58 at the end of the previous year[4] - The total assets increased to CNY 3,246,045,079.45, compared to CNY 2,929,704,604.58 at the end of Q1 2022, reflecting a growth of approximately 11%[16] - The total liabilities rose to CNY 712,936,666.80, up from CNY 447,445,307.03, marking an increase of about 59%[16] - The total current assets amount to 1,755,101,778.18 yuan, an increase from 1,609,891,239.32 yuan at the beginning of the year[14] - The company has a total of 132,009,767.53 yuan in contract assets[14] Cash Flow - The net cash flow from operating activities improved significantly to -¥3,367,415.62, a 89.81% increase compared to -¥33,055,022.37 in the previous year[4] - The company's cash flow from operating activities showed a positive trend, indicating improved liquidity and operational efficiency[18] - Operating cash inflow for the current period was $156,711,271.26, compared to $104,198,451.75 in the previous period, representing a 50.4% increase[19] - Net cash outflow from operating activities was -$3,367,415.62, an improvement from -$33,055,022.37 in the previous period[19] - Cash inflow from financing activities totaled $250,000,000.00, with a net cash inflow of $247,293,154.72, a significant recovery from -$240,411,585.24 in the previous period[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,106[10] - The largest shareholder, Shao Chunnan, holds 18.72% of shares, totaling 20,250,000 shares[10] - The second largest shareholder, Lou Jinfang, holds 12.48% of shares, totaling 13,500,000 shares[10] Expenses - The company experienced a 116.60% increase in management expenses, totaling ¥30,143,084.38, primarily due to the amortization of equity incentive expenses granted in June 2022[8] - Research and development expenses for Q1 2023 were CNY 44,638,654.42, slightly higher than CNY 44,014,040.32 in Q1 2022, demonstrating continued investment in innovation[16] Contract Liabilities - The company reported a significant increase in contract liabilities to CNY 86,171,587.59, up from CNY 62,612,015.80, indicating strong future revenue commitments[16] - The company's contract liabilities increased by 37.63% to ¥86,171,587.59, driven by new customer orders[7] Cash and Equivalents - Cash and cash equivalents at the end of the period are 1,281,825,787.43 yuan, up from 1,238,789,220.70 yuan at the beginning of the year[14] - The net increase in cash and cash equivalents for the current period was $34,640,839.10, compared to a decrease of -$380,966,463.46 in the previous period[20] - The ending balance of cash and cash equivalents was $1,245,708,720.63, down from $1,628,035,047.39 in the previous period[20] Audit Status - The company’s first quarter report was not audited[21]

证券代码：301096 证券简称：百诚医药 杭州百诚医药科技股份有限公司 投资者关系活动记录表 编号：2023-003 二、问答环节 1、问：尊敬的董事长您好，请教公司在中药研究方面的布 局 以及盈利模式，盈利前景如何？ 您好！公司在中药方面进行研发布局，成立了公司中药天然 药物研发中心，主要从事中药新药、经典名方、同名同方、 院内制剂及大健康产品（保健品、特医食品、医疗器械等） 的研究转化及开发。盈利模式主要有受托服务和技术成果转 化，盈利前景比较看好。谢谢。 2、问：您好，请问下中药管线目前的情况和未来的发展谢 谢。 您好！主要有中药新药、经典名方、同名同方、院内制剂及 大健康产品（保健品、特医食品、医疗器械等）的研究转化 | 及开发，目前有多个产品研发中。未来中药的研发将是公司 | | --- | | 收入和利润新的增长点。谢谢。 | | 3、问：公司如何看待 CRO 行业在国内的发展现状和成长潜 | | 力？ | | 您好，从国内来看，随着全球医药外包转移、国内外包需求 | | 释放、原研药数量的增加以及医疗卫生费用日益增长而带来 | | 的控费需求等趋势变化，我国 CRO 行业成长空间大，市场竞 | ...

Financial Performance - The company's revenue for 2022 was CNY 607,410,539.16, representing a 62.27% increase compared to CNY 374,311,815.33 in 2021[22]. - The net profit attributable to shareholders for 2022 was CNY 194,163,970.20, a 74.78% increase from CNY 111,088,253.50 in 2021[22]. - The net cash flow from operating activities reached CNY 259,413,420.62, up 78.38% from CNY 145,424,030.12 in 2021[22]. - Basic earnings per share for 2022 were CNY 1.80, a 31.39% increase from CNY 1.37 in 2021[22]. - The company achieved a revenue of CNY 607.41 million in 2022, representing a year-on-year growth of 62.27%[101]. - The net profit attributable to shareholders reached CNY 194.16 million, an increase of 74.78% compared to the previous year[101]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 20%[188]. - The company anticipates a revenue growth forecast of 20% for the upcoming fiscal year, driven by new product launches and market expansion strategies[161]. Research and Development - The company has a focus on research and development of new products and technologies, although specific figures are not provided in the available content[3]. - The company’s R&D expenses amounted to CNY 166.07 million, reflecting a 104.68% increase year-on-year, indicating a strong commitment to innovation[102]. - The company is currently developing 8 innovative drug projects targeting various pathways, with BIOS-0618 having received clinical approval and entering Phase I trials[61]. - The company is focusing on 8 innovative drug projects, all classified as Class 1 new drugs, targeting areas such as neuropathic pain and tumors, indicating a broad market potential[90]. - The company has established a comprehensive drug R&D and production service platform, integrating pharmaceutical research, clinical trials, and custom production[51]. - The company is focused on enhancing its research and development capabilities to innovate new technologies and products[180]. - The company is investing 200 million yuan in new technology for drug development, which is anticipated to improve efficiency by 25%[188]. Market Expansion and Strategy - Future plans and development strategies are outlined, with a caution for investors regarding potential risks[3]. - The company plans to enhance its market expansion efforts in response to the increasing demand for CRO services driven by the aging population and healthcare reforms in China[36]. - The company aims to retain sales rights sharing in contracts with clients, ensuring stable revenue through profit-sharing during the drug's effective lifecycle[57]. - The company plans to increase its market presence by expanding its marketing channels and targeting both domestic and international markets, particularly in traditional Chinese medicine and biopharmaceuticals[148]. - The company is exploring new market opportunities to expand its product offerings and reach[194]. - The company is actively pursuing mergers and acquisitions to enhance its market position and expand its product offerings[161]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[164]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the meeting[3]. - The company is committed to maintaining a robust governance structure, as indicated by the presence of the board and supervisory committees[3]. - The financial report is subject to audit by a registered accounting firm, ensuring transparency and accountability[9]. - The company has established a comprehensive quality management system to ensure data authenticity and reliability, including independent QA department oversight[96]. - The company has no significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[169]. - The company maintains complete independence in assets, personnel, finance, organization, and business operations from its controlling shareholders[170]. Operational Efficiency - The company has established a robust internal management system to enhance operational efficiency and protect shareholder interests[169]. - The company has a stable and dedicated R&D team led by experienced professionals, enhancing project initiation and industry trend forecasting capabilities[99]. - The company is committed to continuous improvement in its management systems to handle the increased scale of operations and maintain efficiency[152]. - The company has implemented a stock incentive plan for 197 executives and core employees, which has resulted in significant share-based payment expenses[156]. - The company is focused on optimizing its human resource management system to maximize employee value and overall profitability[156]. Risk Management - The company has outlined its risk management strategies in the management discussion section, which is crucial for future growth[3]. - The company recognizes the risks associated with drug development failures and long development cycles, and it is implementing strategies to mitigate these risks through talent acquisition and process optimization[150][152]. - The company acknowledges the potential for business fluctuations due to changes in industry policies, market competition, and customer demand[154]. Investment and Financial Management - The company raised a total of ¥2,152,516,693.20 from its initial public offering, with a net amount of ¥1,863,430,088.41 after deducting issuance costs[136]. - The company’s investment activities resulted in a net cash outflow of CNY 690.87 million, a 175.07% increase in outflow compared to the previous year[102]. - The company has ongoing significant non-equity investments, including a project with an investment amount of ¥225,800,000 for research and testing[131]. - The company has approved the proposal to change its registered capital, address, and type, along with amending the articles of association[198]. Customer and Market Metrics - User data indicates a steady growth in customer base, contributing to an overall revenue increase of 15% year-over-year[161]. - User data indicates a growth in active users, reaching 2 million, which is a 15% increase compared to the previous year[188]. - The company has secured a significant number of new orders, indicating strong demand for its products in the market[161]. Product Development - New product development includes the launch of three innovative drug formulations, expected to contribute an additional 300 million yuan in revenue[188]. - The company is developing multiple new drugs targeting various diseases, including a first-class new drug for cancer and a new inhalation drug for asthma[121].

证券代码：301096 证券简称：百诚医药 公告编号：2023-014 杭州百诚医药科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 （问题征集专题页面二维码） 特此公告。 杭州百诚医药科技股份有限公司董事会 杭州百诚医药科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 29 日在 巨潮资讯网（http://www.cninfo.com.cn）披露了《2022 年年度报告》及其摘要。 为了方便投资者了解公司 2022 年度业绩的相关情况，公司定于 2023 年 4 月 12 日（星期三）15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说明会 将采用网络远程的方式举行，投资者可登录全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有:公司董事长兼总经理楼金芳女士，董事、副总经理兼董 事会秘书刘一凡女士，财务总监颜栋波先生，独立董事任成先生，保荐代表人余波先 生。 为充分尊重投资者、提升交流的针对性 ...

证券代码：301096 证券简称：百诚医药 杭州百诚医药科技股份有限公司 投资者关系活动记录表 编号：2022-029 | --- | --- | --- | --- | --- | --- | --- | |--------------|-------------------------------|------------------------------------------------------|-------|-------|-----------------------------------------------------------------------------------------------------------|----------| | 投资者关系活 | 特定对象调研 | 分析师会议 | | | | | | 动类别 | | □媒体采访 □业绩说明会 | | | | | | | □新闻发布会 | □路演活动 | | | | | | | □现场参观 | | | | | | | | 其他 （电话） | | | | | | | 参与单位名称 | | 长城基金：龙宇飞；信达医 ...

Group 1: Company Overview - The company is a comprehensive pharmaceutical technology R&D enterprise focused on pharmaceutical research, providing drug development services and technology transfer [1] - It adopts a dual development strategy of "entrusted R&D services + R&D technology results transformation" [1] - The company has established strong core competitive advantages in pharmaceutical research and bioequivalence testing services [1] Group 2: R&D Platforms and Collaborations - The company has created various R&D platforms, including innovative drug R&D, generic drug evaluation, and bioequivalence (BE) studies, enhancing its core technical advantages [3] - Strategic partnerships with hospitals like Wenzhou Medical University Second Affiliated Hospital and Dongyang Hengdian Hospital facilitate BE clinical trials at lower costs compared to similar hospitals in Hangzhou [3] Group 3: Impact of Centralized Procurement - Centralized procurement has become normalized, with a procurement cycle of 1-3 years for winning drugs, allowing new products to participate in national procurement [3] - The number of participating manufacturers in centralized procurement is increasing, with the maximum number of winning companies rising from 1 to 10, which helps ensure drug supply [3] Group 4: Revenue Sources and Project Rights - The company's revenue primarily comes from entrusted R&D services and technology transfer, with projects categorized into those with and without sales rights sharing [4] - In the first half of 2021, the company earned a revenue share of 12.62 million yuan (including tax) from a collaboration with Huayuan Pharmaceutical for Valsartan Amlodipine tablets [4]

Company Overview - Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. focuses on technology development as a core aspect of its comprehensive pharmaceutical R&D services, including CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services [2][3]. - The company has provided integrated R&D services to over 300 clients, completing more than 400 projects in pharmaceutical research and clinical trials [3]. Business Operations - The main business areas include generic drug development, quality and efficacy consistency evaluation, custom R&D production services, and innovative drug development [3]. - As of December 31, 2021, the company operated in a laboratory and office space of 18,000 m² with 765 employees and advanced equipment [3]. Infrastructure Development - The company is constructing a new headquarters and R&D center in Linping District, Hangzhou, covering 46.18 acres, expected to be operational by mid-2023, increasing the laboratory and office space to 73,900 m² [3][5]. - The subsidiary, Zhejiang Saime, has a custom R&D production base covering over 180 acres, with a construction area of 137,100 m² and an investment of 437.804 million yuan as of December 31, 2021 [3]. Financial Performance - In the second half of 2021, Zhejiang Saime's CDMO business generated revenue of 9.4014 million yuan, supporting 57 commissioned R&D projects [3]. - The company registered 62 projects during the reporting period, receiving approvals for 23, including two projects as the first in the nation [3]. Future Projections - The CDMO production capacity is projected to reach 156.57 tons of raw materials and 3 billion oral solid dosage forms annually after the completion of the second phase of construction [4]. - The company anticipates continued growth in the pharmaceutical market driven by an aging population, urbanization, and increased disposable income, with a strong focus on generic drugs [4]. Talent Acquisition and Development - The company is actively recruiting specialized personnel in pharmacy and medicine to meet the increasing project demands, supported by a recent stock incentive plan to stabilize and attract talent [5].